Costeff Syndrome (3-methylglutaconic aciduria type III) is a rare genetic condition causing early-onset optic atrophy along with movement difficulties such as chorea and spasticity later in life. Genetic testing and specialized metabolic/neuro-ophthalmology care for this condition are essentially unavailable within Tanzania. Optic Atrophy Treatment Center works with Tanzanian families exploring stem cell therapy for the optic nerve component of Costeff Syndrome.
As an extremely rare metabolic-genetic condition, Costeff Syndrome requires specialized diagnostic testing (urine organic acid analysis, genetic testing for the OPA3 gene) that is not available within Tanzania. Families often travel abroad for both diagnostic confirmation and to explore treatment options for the optic nerve damage.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Stem cell therapy is studied for its potential to help support optic nerve tissue affected by Costeff Syndrome. It addresses the vision component only — the movement-related features (chorea, spasticity) require ongoing management by a neurologist.
Suitability depends on the stage and cause of the condition. Before travelling, our team reviews:

From the first time we talked to the team and in all the discussions that followed, the team was really easy to talk to and explained everything clearly. They took the time to understand what was going on

Highly trustworthy! From consultation to follow-up, the team was responsive and dedicated. Excellent facilities and patient-focused approach. the team was veey good
“No, our evaluation and treatment address the optic nerve/vision component only. Movement-related symptoms should be managed by a neurologist.”
” It’s helpful if available, but not mandatory — our team can review based on clinical history and OCT/visual field findings.”
“OCT scan, visual field test, any metabolic/genetic test results, and a summary of when vision loss and movement symptoms began.”

We would love to hear from you! Please fill out the form below.